RAINBOW: Demographic and baseline characteristics were similar between treatment arms¹⁻²

RAINBOW: DEMOGRAPHIC AND BASELINE CHARACTERISTICS2,3

RAINBOW demographic and baseline characteristics

ECOG=Eastern Cooperative Oncology Group; PS=performance status.

*By self-report.

References:
  1. CYRAMZA (ramucirumab) [package insert]. India, Eli Lilly & Company (India) Pvt. Ltd.
  2. Wilke H, Muro K, Van Cutsem E, et al; for the RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224-1235.
  3. Data on file, Eli Lilly and Company. ONC20141014a.
Top